Appendix B-3 

B

Appendix B_Web.indd 3 11/1/2021 10:27:00 AM United States Vaccine Names United States Vaccines Vaccine Trade Name Abbreviation Manufacturer Route Doses in Routine Series Approved Ages 

Adenovirus Adenovirus Type 4 & Type 7 N/A Teva Pharmaceutical Industries Ltd. Oral (2 Tablets) 1 17-50 years L

pf

Anthrax BioThrax® AVA Emergent BioSolutions IM 3 18-65 years C

a

Cholera VaxchoraTM† N/A Emergent BioSolutions Oral (Liquid) 1 18-64 years L

DTaP Daptacel® DTaP Sanofi IM 5 6 weeks-6 years I

InfanrixTM DTaP GlaxoSmithKline IM 5 6 weeks-6 years I

DT N/A (Generic) DT Sanofi IM 5 6 weeks-6 years I

wc

Haemophilus influenzae type b (Hib) ActHIB® Hib (PRP-T) Sanofi IM 4 2 months-5 years I

c

HiberixTM Hib (PRP-T) GlaxoSmithKline IM 4 6 weeks- 4 years I

c

PedvaxHIB® Hib (PRP-OMP) Merck IM 3 2-71 months I

(

Hepatitis A HavrixTM HepA GlaxoSmithKline IM 2 Pediatric: 12 months-18 years; Adult: ≥19 years I

Vaqta® HepA Merck IM 2 Pediatric: 12 months-18 years; Adult: ≥19 years I

Hepatitis B Engerix-BTM HepB GlaxoSmithKline IM 3 Pediatric: Birth-19 years Adult: ≥20 years R

Recombivax HB® HepB Merck IM 3 Pediatric: Birth-19 years Adult: ≥20 years R

Heplisav-B® HepB Dynavax Technologies IM 2 ≥18 years R

Herpes Zoster (Shingles) ShingrixTM RZV GlaxoSmithKline IM 2 ≥50 years R

Appendix B_Web.indd 3 11/1/2021 10:27:00 AM 
Appendix B-4

B

Appendix B_Web.indd 4 11/1/2021 10:27:00 AM Vaccine Trade Name Abbreviation Manufacturer Route Doses in Routine Series Approved Ages 

Human Papillomavirus (HPV) Gardasil® 9 9vHPV Merck IM 2 or 3 9-45 years Influenza* Afluria Quadrivalent® IIV4 Seqirus IM 1 or 2 ≥6 months 

Fluad® Quadrivalent aIIV4 Seqirus IM 1 ≥65 years 

FluarixTM Quadrivalent IIV4 GlaxoSmithKline IM 1 or 2 ≥6 months 

Flublok® Quadrivalent RIV4 Sanofi IM 1 ≥18 years 

Flucelvax® Quadrivalent ccIIV4 Seqirus IM 1 or 2 ≥2 years 

FluLavalTM Quadrivalent IIV4 GlaxoSmithKline IM 1 or 2 ≥6 months 

FluMist® Quadrivalent LAIV4 AstraZeneca Intranasal 1 or 2 2-49 years 

Fluzone® Quadrivalent IIV4 Sanofi IM 1 or 2 ≥6 months 

Fluzone® High-Dose Quadrivalent HD-IIV4 Sanofi IM 1 ≥65 years 

Japanese encephalitis Ixiaro® JE Valneva IM 2 ≥2 months Measles, Mumps, Rubella M-M-R® II MMR Merck SC 2 ≥12 months Meningococcal (serogroups A, C, W, and Y) Menactra® MenACWY-D Sanofi IM 2 9 months-55 years 

MenquadfiTM MenACWY-TT Sanofi IM 2 ≥2 years 

MenveoTM MenACWY-CRM GlaxoSmithKline IM 2 2 months-55 years 

Meningococcal (serogroup B) Trumenba® MenB-FHbp Pfizer IM 2 or 3 10-25 years 

BexseroTM MenB-4C GlaxoSmithKline IM 2 10-25 years 

Appendix B_Web.indd 4 11/1/2021 10:27:00 AM 
Appendix B-5 

B

Appendix B_Web.indd 5 11/1/2021 10:27:00 AM Appendix B_Web.indd 5 11/1/2021 10:27:00 AM Vaccine Trade Name Abbreviation Manufacturer Route Doses in Routine Series Approved Ages 

Pneumococcal Pneumovax® 23 PPSV23 Merck IM or SC 1 ≥2 years I

Prevnar 13® PCV13 Pfizer IM 4 (pediatric) 1 (adult) Pediatric: ≥6 weeks Adult: >65 years I

c

Polio Ipol® IPV Sanofi IM or SC 4 ≥6 weeks IRabies Imovax® N/A Sanofi IM 2-3 (pre-exposure) 4 (post-exposure) All ages I

RabAvert® N/A Bavarian Nordic IM 2-3 (pre-exposure) 4 (post-exposure) All ages I

Rotavirus RotaTeq® RV5 Merck Oral (Liquid) 3 6-32 weeks L

RotarixTM RV1 GlaxoSmithKline Oral (Liquid) 2 6-24 weeks L

Tetanus, (reduced) Diphtheria Tenivac® Td Sanofi IM 1 (Every 10 years) ≥7 years I

TdVaxTM Td Massachusetts Biological Labs IM 1 (Every 10 years) ≥7 years I

Tetanus, (reduced) Diphtheria, (reduced) Pertussis BoostrixTM Tdap GlaxoSmithKline IM 1 ≥10 years I

Adacel® Tdap Sanofi IM 1 10-64 years I

Typhoid Typhim Vi® N/A Sanofi IM 1 ≥2 years I

Vivotif® N/A Emergent BioSolutions Oral (Capsules) 4 ≥6 years L

Varicella Varivax® VAR Merck SC 2 ≥12 months L

Smallpox (Vaccinia) ACAM2000® — Emergent BioSolutions Percutaneous 1 All ages LSmallpox and Monkeypox JYNNEOS® — Bavarian Nordic SC 2 ≥18 years LYellow Fever YF-Vax® YF Sanofi SC 1 ≥9 months L

The abbreviations on this table (Column 3) were standardized jointly by staf of the Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices (

of the Morbidity and Mortality Weekly Report (MMWR), the editor of Epidemiology and Prevention of Vaccine-Preventable Diseases (the Pink Book), ACIP members, and liaison These abbreviations are intended to provide a uniform approach to vaccine references used in ACIP Recommendations and Policy Notes published in the MMWR, the Pink BookPediatrics Red Book, and in the U.S. immunization schedules for children, adolescents, and adults. In descriptions of combination vaccines, a hyphen (-) indicates products in whsupplied in their fnal (combined) form by the manufacturer; a slash ( / ) indicates products in which active components must be mixed by the user. “Doses in a Routine Series” (Column 6) refects doses administered to a healthy patient at the recommended ages. It does not necessarily refect schedules for patients with healtfactors, alternative schedules, catch-up schedules, or booster doses not part of an initial series. For some combination vaccines, this column represents the routine number of dnecessarily the total number of doses in a complete series for the components. (For example, Kinrix or Quadracel may be used for only 1 dose of multi-dose DTaP and IPV series

“Adj.” in the “Comments” column indicates that the vaccine contains an adjuvant. A hyphen in an age range means “through” (i.e., “6 weeks-6 years” means 6 weeks through 6 years [to the 7th birthday]). *All infuenza vaccines in this table are 2021-2022 northern hemisphere formulations. For the most current recommendations on infuenza, see: https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specifc/fu.html †May be limited in supply as manufacturer has temporarily stopped production 
Appendix B-6

B

Appendix B_Web.indd 6 11/1/2021 10:27:00 AM Appendix B_Web.indd 6 11/1/2021 10:27:00 AM United States Combination Vaccines Vaccine Trade Name Abbreviation Manufacturer Route Doses in Routine Series Approved Ages 

DTaP, Polio KinrixTM DTaP-IPV GlaxoSmithKline IM 1 4-6 years Ina

5th 

Quadracel® DTaP-IPV Sanofi IM 1 4-6 years Ina

5th 

DTaP, hepatitis B, Polio PediarixTM DTaP-HepB-IPV GlaxoSmithKline IM 3 6 weeks-6 years Ina

2, 4

DTaP, Polio, Haemophilus influenzae type b Pentacel® DTaP-IPV/Hib Sanofi IM 4 6 weeks-4 years 4 In

for 

DTaP, Polio, Haemophilus influenzae type b, hepatitis B VaxelisTM DTaP-IPV-Hib-HepB Sanofi IM 3 6 weeks-4 years Ina

2, 4

Hepatitis A, Hepatitis B TwinrixTM HepA-HepB GlaxoSmithKline IM 3 ≥18 years Ina

Ped

Measles, Mumps, Rubella, Varicella ProQuad® MMRV Merck SC 2 12 months- 12 years Liv

The abbreviations on this table (Column 3) were standardized jointly by staf of the Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices (

of the Morbidity and Mortality Weekly Report (MMWR), the editor of Epidemiology and Prevention of Vaccine-Preventable Diseases (the Pink Book), ACIP members, and liaison These abbreviations are intended to provide a uniform approach to vaccine references used in ACIP Recommendations and Policy Notes published in the MMWR, the Pink BookPediatrics Red Book, and in the U.S. immunization schedules for children, adolescents, and adults. In descriptions of combination vaccines, a hyphen (-) indicates products in whsupplied in their fnal (combined) form by the manufacturer; a slash ( / ) indicates products in which active components must be mixed by the user. “Doses in a Routine Series” (Column 6) refects doses administered to a healthy patient at the recommended ages. It does not necessarily refect schedules for patients with healtfactors, alternative schedules, catch-up schedules, or booster doses not part of an initial series. For some combination vaccines, this column represents the routine number of dnecessarily the total number of doses in a complete series for the components. (For example, Kinrix or Quadracel may be used for only 1 dose of multi-dose DTaP and IPV series

“Adj.” in the “Comments” column indicates that the vaccine contains an adjuvant. A hyphen in an age range means “through” (i.e., “6 weeks-6 years” means 6 weeks through 6 years [to the 7th birthday]). November 2021